AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31478780 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT scores in 2018
Number of subjects: 6
Study 31478780 — intervention group
Group type: COMPARATOR
Intervention: AUDIT scores in 2014
Number of subjects: 6
Study 27575014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task walking (hearing a sound, turning head to watch a number, verbalizing it)
Number of subjects: 85
Study 27575014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task walking
Number of subjects: 85
Study 27575014 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects affected by cerebral palsy and stroke
Number of subjects: 85
Study 26817809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at 30% of maximal inspiratory pressure for 15 minutes twice a day, 7 days a week, for 12 weeks alongside standard medical treatment.
Number of subjects: 38
Study 26817809 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment only (control group).
Number of subjects: 38
Study 24837137 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m²) with zoledronic acid (group DZ)
Number of subjects: 100
Study 24837137 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m²) without zoledronic acid (group D)
Number of subjects: 100
Study 22011899 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 47
Study 22011899 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline and CBT
Number of subjects: 47
Study 22011899 — intervention group
Group type: COMPARATOR
Intervention: Placebo and CBT
Number of subjects: 47
Study 22011899 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 47
Study 19185957 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin breakfast
Number of subjects: 24
Study 19185957 — intervention group
Group type: EXPERIMENTAL
Intervention: gelatin + TRP breakfast
Number of subjects: 24
Study 19185957 — intervention group
Group type: COMPARATOR
Intervention: casein, soy, or whey-GMP breakfast
Number of subjects: 24
Study 19185957 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin or gelatin (+TRP) breakfast
Number of subjects: 24
Study 17257533 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (celecoxib)
Number of subjects: 29
Study 17257533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15748470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite + vitamin E (A group)
Number of subjects: 90
Study 15748470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite only (B group)
Number of subjects: 90
Study 15748470 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 11437770 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia with N2O
Number of subjects: 24
Study 11437770 — intervention group
Group type: COMPARATOR
Intervention: Anaesthesia without N2O
Number of subjects: 24
Study 9543976 — intervention group
Group type: EXPERIMENTAL
Intervention: hyper-oxygenated fatty acid esters solution
Number of subjects: 28
Study 7820356 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure followed by live exposure (Group 1)
Number of subjects: 14
Study 7820356 — intervention group
Group type: EXPERIMENTAL
Intervention: Live exposure followed by imaginal exposure (Group 2)
Number of subjects: 14
Study 7820356 — intervention group
Group type: COMPARATOR
Intervention: Live exposure (as compared to imaginal exposure)
Number of subjects: 14
Study 2898536 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (chemotherapy plus radiotherapy)
Number of subjects: 43
Study 2898536 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (SMF: streptozocin, mitomycin, and 5-fluorouracil)
Number of subjects: 43
Study 2898536 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy
Number of subjects: 43
Study 2898536 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (SMF)
Number of subjects: 43
Study 31397771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 70
Study 31397771 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Band (RB) exercise
Number of subjects: 70
Study 31397771 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 70
Study 28557299 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help with up to 3 h of therapist assistance
Number of subjects: 42
Study 28557299 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 42
Study 25427944 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine
Number of subjects: 157
Study 25427944 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 157
Study 23865955 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 184480
Study 21639810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter)
Number of subjects: 502
Study 21639810 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (850 mg per square meter) plus placebo
Number of subjects: 502
Study 21639810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus dacarbazine
Number of subjects: 502
Study 21639810 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine plus placebo
Number of subjects: 502
Study 20048532 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercises (frequency 35 Hz, intensity high, amplitude 4 mm) during dynamic (squatting, calf raises) and static (standing) exercises for 3 minutes
Number of subjects: 20
Study 20048532 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf raises with whole body vibration
Number of subjects: 20
Study 20048532 — intervention group
Group type: COMPARATOR
Intervention: Calf raises without whole body vibration
Number of subjects: 20
Study 16672833 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifiable Activity Questionnaire (MAQ; past year)
Number of subjects: 3234
Study 16672833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐Level Physical Activity Recall (LOPAR; past 7 d)
Number of subjects: 3234
Study 16672833 — intervention group
Group type: EXPERIMENTAL
Intervention: Third National Health and Nutrition Examination Survey (NHANES III; past month)
Number of subjects: 3234
Study 14748941 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant mixture (Se 150 microg, retinyl acetate mg, ascorbic acid 120 mg, alpha‐tocopheryl succinate 20 mg)
Number of subjects: 17
Study 14748941 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant mixture
Number of subjects: 17
Study 11295719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam
Number of subjects: 406
Study 11295719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 9649986 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms kg‐1
Number of subjects: 120
Study 9649986 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 120
Study 9649986 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 80 micrograms kg‐1
Number of subjects: 120
Study 9649986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 8198414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate (165 infants received the drug)
Number of subjects: 334
Study 8198414 — intervention group
Group type: COMPARATOR
Intervention: Control (169 infants, only 1 received ethamsylate)
Number of subjects: 334
Study 8198414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 334
Study 8198414 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 334
Study 2830918 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 2.5 mg b.i.d.
Number of subjects: 14
Study 2830918 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 5 mg b.i.d.
Number of subjects: 14
Study 2830918 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 10 mg b.i.d.
Number of subjects: 14
Study 2830918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30187572 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of 2% lidocaine solution 20mL (LID, n=64)
Number of subjects: 128
Study 30187572 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 20mL (control, n=64)
Number of subjects: 128
Study 29364340 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus SP1)
Number of subjects: 47
Study 29364340 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic (Azithromycin 500mg)
Number of subjects: 47
Study 29364340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 26847966 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 357
Study 25179975 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed surgical closure following a vacuum‐assisted closure system (VAC)
Number of subjects: 58
Study 25179975 — intervention group
Group type: COMPARATOR
Intervention: Primary surgical closure (PSC)
Number of subjects: 58
Study 22549286 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 400 mg
Number of subjects: 161
Study 22549286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 20626422 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally placed submerged implants (Group 1)
Number of subjects: 46
Study 20626422 — intervention group
Group type: COMPARATOR
Intervention: Early-placed submerged implants (Group 2)
Number of subjects: 46
Study 20626422 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 implants
Number of subjects: 46
Study 20626422 — intervention group
Group type: COMPARATOR
Intervention: Group 2 implants
Number of subjects: 46
Study 20626422 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 46
Study 17141318 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline intraocular pressure (IOP) measurements including mean diurnal, peak, trough, IOP range (peak - trough), and standard deviation (SD) of IOP.
Number of subjects: 190
Study 17141318 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unilateral VF loss (n = 53)
Number of subjects: 190
Study 17141318 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bilateral VF loss (n = 137)
Number of subjects: 190
Study 17141318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-classified contingency tables analysis
Number of subjects: 190
Study 15618783 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (n = 6)
Number of subjects: 10
Study 15618783 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (n = 4)
Number of subjects: 10
Study 11996262 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (group C) - the vein was stripped, distended, and stored in saline
Number of subjects: 156
Study 11996262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate technique (group I) - the vein was stripped, local application of papaverine was used instead of distention, and the vessel was then stored in heparinized blood
Number of subjects: 156
Study 11996262 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch technique (group NT) - the vein was harvested with surrounding tissue, not distended, and stored in heparinized blood
Number of subjects: 156
Study 10404741 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA) for acidic fibroblast growth factor (aFGF)
Number of subjects: 0
Study 7733123 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT 50 IU/d
Number of subjects: 251
Study 7733123 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT 200 IU/d
Number of subjects: 251
Study 7733123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 1972494 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of axillary lymph node micrometastases
Number of subjects: 921
Study 1972494 — intervention group
Group type: COMPARATOR
Intervention: Negative nodes on serial sectioning
Number of subjects: 921
Study 7188714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 11
Study 7188714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31107344 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin (SCIG), a 20% solution stabilized with L‐proline, FDA-approved for CIDP maintenance therapy.
Number of subjects: 0
Study 31107344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28370991 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene cap (NeoCap)
Number of subjects: 80
Study 28370991 — intervention group
Group type: COMPARATOR
Intervention: Cotton cap (Control)
Number of subjects: 80
Study 24786301 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin group (negative troponin and copeptin values at admission)
Number of subjects: 902
Study 24786301 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 902
Study 24786301 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (per protocol analysis)
Number of subjects: 902
Study 24786301 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin group (per protocol analysis)
Number of subjects: 902
Study 24215419 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal Atrial Fibrillation (AF) group
Number of subjects: 51
Study 24215419 — intervention group
Group type: COMPARATOR
Intervention: Control group (without paroxysmal AF)
Number of subjects: 51
Study 22270266 — intervention group
Group type: EXPERIMENTAL
Intervention: Race-discordant relationships (black patient, white provider) with collaborative communication
Number of subjects: 597
Study 22270266 — intervention group
Group type: EXPERIMENTAL
Intervention: Race-discordant relationships (black patient, white provider) with less collaborative communication
Number of subjects: 597
Study 22270266 — intervention group
Group type: COMPARATOR
Intervention: Race-concordant relationships (black patient, black provider)
Number of subjects: 597
Study 19403902 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR24 group (telaprevir 1250 mg on day 1 and 750 mg every 8 hours for 12 weeks, plus peginterferon alfa‐2a and ribavirin for 24 weeks)
Number of subjects: 250
Study 19403902 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR48 group (telaprevir for 12 weeks, plus peginterferon alfa‐2a and ribavirin for 48 weeks)
Number of subjects: 250
Study 19403902 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR12 group (telaprevir for 12 weeks, plus peginterferon alfa‐2a and ribavirin for 12 weeks)
Number of subjects: 250
Study 19403902 — intervention group
Group type: COMPARATOR
Intervention: PR48 group (peginterferon alfa‐2a and ribavirin for 48 weeks, plus telaprevir-matched placebo for 12 weeks)
Number of subjects: 250
Study 19403902 — intervention group
Group type: EXPERIMENTAL
Intervention: All telaprevir groups
Number of subjects: 250
Study 17848497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 232
Study 17848497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 15086491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-coated dialyzer (VE)
Number of subjects: 10
Study 15086491 — intervention group
Group type: COMPARATOR
Intervention: Cellulosic membrane (CM)
Number of subjects: 10
Study 11116287 — intervention group
Group type: EXPERIMENTAL
Intervention: Vatanidipine
Number of subjects: 0
Study 9709043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol 9 film
Number of subjects: 1292
Study 9709043 — intervention group
Group type: COMPARATOR
Intervention: Placebo film
Number of subjects: 1292
Study 8011392 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadodiamide injection
Number of subjects: 49
Study 8011392 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadodiamide injection
Number of subjects: 49
Study 8011392 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diagnostic utility of gadodiamide injection
Number of subjects: 49
Study 8011392 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety profile of gadodiamide injection
Number of subjects: 49
Study 1954210 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-green laser
Number of subjects: 25
Study 1954210 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow laser
Number of subjects: 25
Study 1954210 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange laser
Number of subjects: 25
Study 209881 — intervention group
Group type: COMPARATOR
Intervention: CTX (Cytoxan)
Number of subjects: 37
Study 209881 — intervention group
Group type: COMPARATOR
Intervention: COMF (CTX, oncovin, methotrexate and 5-FU)
Number of subjects: 37
Study 209881 — intervention group
Group type: EXPERIMENTAL
Intervention: AMCOF (adriamycin, methotrexate, CTX, oncovin and 5-FU)
Number of subjects: 37
Study 209881 — intervention group
Group type: COMPARATOR
Intervention: CTX (for small cell carcinoma)
Number of subjects: 37
Study 209881 — intervention group
Group type: COMPARATOR
Intervention: COMF (for small cell carcinoma)
Number of subjects: 37
Study 209881 — intervention group
Group type: EXPERIMENTAL
Intervention: AMCOF (for small cell carcinoma)
Number of subjects: 37
Study 209881 — intervention group
Group type: COMPARATOR
Intervention: CTX (for adenocarcinoma or epidermoid carcinoma)
Number of subjects: 37
Study 209881 — intervention group
Group type: COMPARATOR
Intervention: COMF (for adenocarcinoma or epidermoid carcinoma)
Number of subjects: 37
Study 209881 — intervention group
Group type: EXPERIMENTAL
Intervention: AMCOF (for adenocarcinoma or epidermoid carcinoma)
Number of subjects: 37
Study 27778151 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 70
Study 27778151 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary intake of magnesium (<250 mg/day)
Number of subjects: 70
Study 27778151 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary intake of magnesium (>250 mg/day)
Number of subjects: 70
Study 27778151 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled metabolic unit balance studies
Number of subjects: 70
Study 25055838 — intervention group
Group type: EXPERIMENTAL
Intervention: mBATRAC (bilateral upper-limb training)
Number of subjects: 60
Study 25055838 — intervention group
Group type: EXPERIMENTAL
Intervention: mCIMT (unilateral upper-limb training)
Number of subjects: 60
Study 25055838 — intervention group
Group type: COMPARATOR
Intervention: DMCT (dose-matched control treatment)
Number of subjects: 60
Study 24210600 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy for 12 weeks
Number of subjects: 53
Study 24210600 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 53
Study 24210600 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 53
Study 22101701 — intervention group
Group type: EXPERIMENTAL
Intervention: SGIP acupuncture therapy
Number of subjects: 63
Study 22101701 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium bromide (control)
Number of subjects: 63
Study 19289935 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia flip chart
Number of subjects: 35
Study 18600327 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in sea water
Number of subjects: 46
Study 18600327 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise in water pool
Number of subjects: 46
Study 15244227 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) from birth
Number of subjects: 34
Study 15244227 — intervention group
Group type: COMPARATOR
Intervention: Incubator care
Number of subjects: 34
Study 11602221 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta 1 and beta 2 receptor antagonist)
Number of subjects: 27
Study 11602221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11602221 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 27
Study 11602221 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion before an injection of placebo
Number of subjects: 27
Study 9595523 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 0
Study 9595523 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 8082098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin as a radiosensitizer with an induction phase of 4500 cGy and two cycles of cisplatin followed by radical surgery (Group A)
Number of subjects: 68
Study 8082098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin as a radiosensitizer with an induction phase of 4500 cGy and two cycles of cisplatin followed by radical radiotherapy (Group B)
Number of subjects: 68
Study 8082098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin as a radiosensitizer with an induction phase of 4500 cGy and two cycles of cisplatin followed by radical surgery or radiotherapy
Number of subjects: 68
Study 2688428 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 213
Study 2688428 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 213
Study 766118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 69
Study 766118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 11903210 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of labor (n = 320)
Number of subjects: 651
Study 11903210 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n = 331)
Number of subjects: 651
Study 31216125 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 31216125 — intervention group
Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 0
Study 29873956 — intervention group
Group type: EXPERIMENTAL
Intervention: MIN‐101 32 mg
Number of subjects: 244
Study 29873956 — intervention group
Group type: EXPERIMENTAL
Intervention: MIN‐101 64 mg
Number of subjects: 244
Study 29873956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244